AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AbCellera's stock with a target price of $14.88, indicating significant growth potential.
Financial Health
AbCellera is generating moderate revenue and cash flow, but its financial position needs improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ABCL
Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketHope & Optimism Portfolio
This collection brings together pioneering companies working to solve humanity's biggest challenges through groundbreaking innovation. These carefully selected stocks represent visionaries building transformative technologies in medicine, energy, and beyond.
Published: June 18, 2025
Explore BasketAI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform-driven discovery
A proprietary single‑cell platform helps find antibody leads quickly, which may speed collaborations — though discovery does not guarantee commercial success.
Partner revenue model
Revenue stems from collaborations, milestones and potential royalties, creating upside tied to partners but also irregular cash flows and dependency risks.
Development uncertainty
Clinical, regulatory and commercial hurdles can delay or derail programmes, making the stock potentially volatile and suitable for risk‑tolerant investors only.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
